Haidar Al-Saig

CAR T-cell therapy in small-cell lung cancer with a focus on DLL3-targeted approaches

Small-cell lung cancer (SCLC) remains a fast-growing, genomically plastic neuroendocrine cancer with poor survival despite chemo-immunotherapy. Converging biological and clinical evidence identifies delta-like ligand 3 (DLL3) as a lineage-linked target expressed in most SCLC with limited normal tissue expression, enabl...